BioCentury | Aug 7, 2006
Strategy

Life after amylin

...peptides that had weight loss or anti-diabetic effects." Two years later, AMLN acquired rights from Restoragen Inc....
BioCentury | Jun 6, 2005
Company News

Arginox management update

...Business: Cardiovascular, Cancer, Autoimmune Hired: David Hathaway as CMO, formerly VP of franchise development at Restoragen Inc. WIR...
BioCentury | Feb 16, 2004
Company News

Can-Fite management update

...Cancer Hired: Ashleigh Palmer as CBO for U.S. corporate development, formerly CEO and chairman of Restoragen Inc. WIR...
BioCentury | Aug 4, 2003
Clinical News

AC2592: Phase II

...to moderate nausea. AMLN has rights to the compound under a December 2002 deal with Restoragen Inc....
BioCentury | Jul 29, 2003
Clinical News

Amylin Phase II CHF data

...to moderate nausea. AMLN has rights to the compound under a December 2002 deal with Restoragen...
BioCentury | Jun 2, 2003
Company News

BresaGen, Restoragen deal

...and peptides. Restoragen previously has filed for bankruptcy protection. BresaGen Ltd. (ASX:BGN; BSGNY), Adelaide, Australia Restoragen Inc....
BioCentury | Jan 6, 2003
Tools & Techniques

AMLN metabolizes GLP-1 assets

...diabetes, has added to its metabolic arsenal by acquiring intellectual property rights to GLP-1 from Restoragen Inc....
...clear, the deal also boosts the company's foothold in the cardiovascular space, providing rights to Restoragen's...
...GLP-1 improves cardiac function, but the molecular mechanisms are not totally worked out," Baron said. Restoragen...
BioCentury | Jan 6, 2003
Company News

Amylin, Restoragen deal

...AMLN acquired from Restoragen rights to a continuous infusion formulation of glucagon-like peptide 1 (GLP-1), which...
...CHF) patients who are ineligible for transplant. AMLN also received rights to patents covering GLP-1. Restoragen...
...in the gut in response to food intake. Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif. Restoragen Inc....
BioCentury | Dec 26, 2002
Company News

Amylin acquires Restoragen CHF compound

...AMLN acquired from Restoragen (Lincoln, Neb.) rights to a continuous infusion formulation of glucagon-like peptide 1...
...CHF) patients who are ineligible for transplant. AMLN also received rights to patents covering GLP-1. Restoragen...
BioCentury | Mar 18, 2002
Clinical News

Betatropin: Phase II

...1.9 kg) after 6 weeks of continuous subcutaneous infusion dosing (see BioCentury, July 9, 2001). Restoragen Inc....
Items per page:
1 - 10 of 18
BioCentury | Aug 7, 2006
Strategy

Life after amylin

...peptides that had weight loss or anti-diabetic effects." Two years later, AMLN acquired rights from Restoragen Inc....
BioCentury | Jun 6, 2005
Company News

Arginox management update

...Business: Cardiovascular, Cancer, Autoimmune Hired: David Hathaway as CMO, formerly VP of franchise development at Restoragen Inc. WIR...
BioCentury | Feb 16, 2004
Company News

Can-Fite management update

...Cancer Hired: Ashleigh Palmer as CBO for U.S. corporate development, formerly CEO and chairman of Restoragen Inc. WIR...
BioCentury | Aug 4, 2003
Clinical News

AC2592: Phase II

...to moderate nausea. AMLN has rights to the compound under a December 2002 deal with Restoragen Inc....
BioCentury | Jul 29, 2003
Clinical News

Amylin Phase II CHF data

...to moderate nausea. AMLN has rights to the compound under a December 2002 deal with Restoragen...
BioCentury | Jun 2, 2003
Company News

BresaGen, Restoragen deal

...and peptides. Restoragen previously has filed for bankruptcy protection. BresaGen Ltd. (ASX:BGN; BSGNY), Adelaide, Australia Restoragen Inc....
BioCentury | Jan 6, 2003
Tools & Techniques

AMLN metabolizes GLP-1 assets

...diabetes, has added to its metabolic arsenal by acquiring intellectual property rights to GLP-1 from Restoragen Inc....
...clear, the deal also boosts the company's foothold in the cardiovascular space, providing rights to Restoragen's...
...GLP-1 improves cardiac function, but the molecular mechanisms are not totally worked out," Baron said. Restoragen...
BioCentury | Jan 6, 2003
Company News

Amylin, Restoragen deal

...AMLN acquired from Restoragen rights to a continuous infusion formulation of glucagon-like peptide 1 (GLP-1), which...
...CHF) patients who are ineligible for transplant. AMLN also received rights to patents covering GLP-1. Restoragen...
...in the gut in response to food intake. Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif. Restoragen Inc....
BioCentury | Dec 26, 2002
Company News

Amylin acquires Restoragen CHF compound

...AMLN acquired from Restoragen (Lincoln, Neb.) rights to a continuous infusion formulation of glucagon-like peptide 1...
...CHF) patients who are ineligible for transplant. AMLN also received rights to patents covering GLP-1. Restoragen...
BioCentury | Mar 18, 2002
Clinical News

Betatropin: Phase II

...1.9 kg) after 6 weeks of continuous subcutaneous infusion dosing (see BioCentury, July 9, 2001). Restoragen Inc....
Items per page:
1 - 10 of 18